Agios Pharma (AGIO) Misses Q4 EPS by 286c

Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($4.23), $2.86 worse than the analyst estimate of ($1.37). Revenue for the quarter came in at $14.24 million versus the consensus estimate of $4.54 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Culp, Inc. (CULP) Misses Q4 EPS by 12c
• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM